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work-related activities consisting of nurse, pharmacist, and/or patient medication 
dispensing, preparation, administration and/or storage. Projects consisted of time and 
cost differences related to 1) three proton pump inhibitor dosage forms and seven 
administration methods, and 2) seven recombinant human growth hormone adminis-
tration methods/devices. Performance-based time data were then used to determine 
personnel/patient opportunity time and supply costs associated with different forms 
of medications and delivery devices. Simulations were developed and used to hold 
independent variables constant so only observed differences between medications and/
or device types could be assessed. Statistical and micro-economic cost analyses were 
conducted speciﬁc to each type of medication and/or device. RESULTS: Processes and 
results show two detailed examples as case studies of how simulation-based research 
may be used to assess health care processes at the micro level. The advantages of isolat-
ing processes of interest from the day-to-day complexity of patient care are demon-
strated. Simulations may also represent an efﬁcient assessment alternative of health 
care processes at the micro level with potential for projection to the macro level as 
compared to live, direct observation, cost-intensive, patient-centered care practice 
evaluations. CONCLUSIONS: Simulation-based time-and-motion and activity-based 
cost analyses allowed detailed micro-level time, workload, and supply evaluations that 
may be projected to the macro level. Professional schools’ simulation laboratories offer 
appropriate settings for such studies.
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ESTIMATING TIME-PROFILED ECONOMIC BURDEN OF ILLNESS
Cao Z1, Song X1, Mark T2
1Thomson Reuters, Cambridge, MA, USA, 2Thomson Reuters, Washington, DC, USA
OBJECTIVES: Demonstrate a technique to characterize the economic burden of illness 
over time, correcting for censoring bias and controlling for difference in baseline 
characteristics between comparison groups. A sample of patients with diagnosis of 
disease A in 2004–2008 were extracted from MarketScan® databases and followed 
to death, disenrollment, or December 31, 2008 (cases). The ﬁrst diagnosis date was 
the index date. Enrollees without disease A were extracted as controls. Their index 
dates were assigned based on the distribution of index dates of cases. METHODS: 
First, Kaplan-Meier estimates for the probability of remaining in the data were calcu-
lated by month and disease status. Failure event was death or disenrollment. Censoring 
event was termination of MarketScan contract or end of study period. Next, total 
health care costs were estimated using generalized linear models (GLM) on the sub-
sample of survivors/enrollees in each month, controlling for disease status, patient 
demographic and clinical characteristics. Adjusted costs were calculated by month and 
disease status using the regression estimates and average characteristics. Estimated 
total costs during the whole follow-up period were the sum of probability of remaining 
in the data multiplied by regression-adjusted costs in each month. RESULTS: At the 
end of year 1, 40.5% of cases deceased or disenrolled from insurance compared to 
13.6% of controls (p < 0.001); at the end of year 4 these ﬁgures were 76.4% and 
30.5%, respectively (p < 0.001). GLM results indicated signiﬁcantly higher cost among 
the group with disease A in each month during follow-up. The adjusted costs based 
on average characteristics was $86,592 for cases vs. $6,178 for controls in the ﬁrst 
year and $151,077 vs. $21,890 in the ﬁrst 4 years. CONCLUSIONS: In studies with 
variable-length follow-up, an estimator combining the survivor probability and regres-
sion-adjusted cost is more robust to censoring bias, and better depicts the economic 
burden of illness over time.
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Databases & 
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THE EFFECT OF LENGTH OF OBSERVATION AND CLAIMS DATA TYPE 
ON ESTIMATES OF COMORBIDITIES AMONG MEDICAID BENEFICIARIES
Banahan III BF, Pace PF
University of Mississippi, Oxford, MS, USA
OBJECTIVES: Researchers frequently use claims data to create comorbidity measures. 
The objective of this project was to examine how the number of months of observation 
data and the type of claims data can affect identiﬁcation of comorbidities. METHODS: 
Inpatient (IP) and outpatient (OT) claims data were used to identify comorbidities for 
beneﬁciaries enrolled in a state Medicaid program. Beneﬁciaries were included if they 
were enrolled for a continuous 24-month period between January 2002 and December 
2004. Data were used to identify the ﬁrst month in which an ICD-9 code appeared 
for each of the 17 comorbidities included in the Charlson Comorbidity Index. The 
D’Hoore scoring system was used to identify ICD-9 codes associated with each 
comorbidity. Results from the IP and OT claims were combined to create overall 
comorbidity measures. RESULTS: The study included a total of 618,337 unique 
patients. The OT claims could identify almost all comorbidities (low of 88.0% for 
myocardial infarctions, high of 99.5% for diabetes). IP claims were much less likely 
to identify comorbidities (low of 11.5% for connective tissue disease, high of 45.7% 
for myocardial infarction). At 12 months, less than half of the beneﬁciaries with 
comorbid events during the 24-month period had been identiﬁed for dementia 
(43.9%), cerobrovascular disease (45.6%), peripheral vascular disease (45.6%), and 
myocardial infarction (48.4%). In contrast, 78.1% of patients with diabetes events 
and 69.0% of patients with chronic pulmonary disease events had been identiﬁed at 
12 months. CONCLUSIONS: The percentage of patients ascribed comorbidities will 
vary signiﬁcantly depending on the number of observation months. Obviously, the 
incidence rate for new events/diagnoses contributes to the increase over time. However, 
researchers must be careful since some comorbidities may not be associated with 
frequent enough physician ofﬁce visits to accurately detect existing comorbidities when 
the number of observation months is short.
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FACILITATE REVIEW AND SUPPORT ANALYSIS
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OBJECTIVES: Clinical literature reviews, especially systematic reviews, require the 
management and evaluation of large amounts of bibliographic data. Although the 
methodology for performing reviews is well documented, few sources share practical 
guidance on how to electronically manage citation data in order to efﬁciently inven-
tory, organize, and assess published material. Spreadsheet tools (e.g., Excel®) give 
researchers unparalleled freedom to manipulate a large volume of information culled 
from source databases (e.g., MEDLINE®); however, many researchers lack a blueprint 
for structuring their data to facilitate review. METHODS: We describe a process of 
erecting “data scaffolding” that is critical to transforming a literature review spread-
sheet into an agile, manipulable source of information that can triage, sort, and report 
on materials retrieved for review. RESULTS: Using a sample of literature data pulled 
from PubMed®, we describe several ideas for adding key structural components to a 
spreadsheet of citations that bring ﬂexibility and functionality to the processes of 
article review and analysis. In doing so, we also describe the hows and whys of 
spreadsheet design to facilitate literature review, such as the importance of the spread-
sheet layout; the addition of ﬂag ﬁelds to use medical subject headings or key words 
to easily sort, organize, identify/retrieve, navigate, and summarize citations; and ways 
of leveraging built-in spreadsheet features such as autoﬁlters, freeze-panes, and sub-
totals that can greatly facilitate the inventory and management of large volumes of 
citation data to support literature reviews. CONCLUSIONS: In an era of increasing 
volumes of published literature and the proliferation of rigorous, formalized, system-
atic and non-systematic reviews, researchers must adapt to growing demands. Existing 
spreadsheet tools can be leveraged to effectively meet these demands, in ways that not 
only provide for greater efﬁciency but in ways that may result in enhanced research 
capabilities.
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RATIONALE AND DEVELOPMENT OF AN ONLINE DIRECTORY OF 
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AND POPULATION RESEARCH
Kamani SA, Goehring Jr EL, Singh VP, Nguyen-Khoa BA, Kapasi AJ, Jones JK
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OBJECTIVES: Large epidemiology studies using population databases are in high 
demand in the current health care environment. Simultaneously, the number of health 
care databases available for research has risen considerably. Increasingly complex 
research questions require population researchers to be more aware of the availability 
and details of databases worldwide. To address this growing need, a web-based direc-
tory with detailed proﬁles of population research databases was developed. 
METHODS: B.R.I.D.G.E. TO DATASM (Beneﬁt-Risk Information for Drug Evalua-
tions) is an advanced version of the original R.A.D.A.R. (Risk Assessment of Drugs 
Analysis & Response) books (1990s; 200+ database proﬁles), and the subsequent 
BRIDGE On-Line version (1999–2003). Over a 20-month period, we convened an 
advisory board, re-branded the website, and updated content. A web development 
ﬁrm built the infrastructure of bridgetodata.org. Content was developed by assessing 
existing database proﬁles and performing extensive literature reviews. A database 
proﬁle template was created with 75 common ﬁelds covering the following categories: 
population type, demographics, physician, drug, diagnosis, procedure, economic, vali-
dation, linkage, and administrative data. We received advisory board feedback at 
multiple stages, and database managers were contacted for listing authorization and 
content approval. A quality assurance process involved systematic review of each 
proﬁle by the primary editor, DGI staff, and database managers. RESULTS: The site 
was launched in November 2009 with 50 database proﬁles from USA, Europe, and 
Asia. It features a web interface designed to perform database searches by ﬁeld type 
and to allow side-by-side comparison of multiple databases. Limitations included a 
short timeline and budgetary constraints. CONCLUSIONS: Development of a web-
based directory of population research database proﬁles will enable the identiﬁcation 
of appropriate databases for pharmacoepidemiologic, economic, and health services 
research. Other applications may include serving as an educational tool and as a model 
for developing new health care databases.
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CAP DATABASE—PROVISION OF OUTPATIENT PROCEDURE DATA IN 
A UNIFIED, STANDARDIZED LANGUAGE
Endel G, Weisser A
Head Association of the Austrian Social Insurance Companies, Vienna, Austria
OBJECTIVES: Due to the heterogeneous health care environment in Austria, data 
about procedures performed in outpatient clinics, ambulatories and in the outpatient 
sector have not been collected in a standardized language. However, this data is crucial 
for planning processes and health services provision. Therefore, the Ministry of Health 
in collaboration with the Austrian Social Security and 3 of 9 Federal States initiated 
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a pilot project to collect this data and make it available for evaluation and planning 
processes in a standardized language according to CAP (Catalog for ambulatory 
procedures). METHODS: The data will be transferred into a new database in two 
data streams to ensure data protection. Data about the patient containing sex, age 
and other characteristics will be sent in a pseudonomyzed way in one data stream. 
Another will contain data about the procedures according to CAP and information 
about contract physicians, outpatient clinics and ambulatories. RESULTS: The new 
database will offer information about what until now has been more or less a black 
spot. It will give information about procedures performed in the ambulatory and 
outpatient sector for all stakeholders participating in this pilot project. CONCLU-
SIONS: Data about outpatient clinics and ambulatories have not been made accessible 
in one database for all participating stakeholders in a standardized language until now. 
The initiated pilot project and the database created therewith offer an opportunity to 
cover this lack of information.
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Modeling Methods
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RULING OUT EXTENDLY DOMINATED OPTIONS USING  
AN ICER MATRIX
O’Day K, Meissner B, Bramley T
Xcenda, Palm Harbor, FL, USA
BACKGROUND: Incremental cost-effectiveness ratios (ICERs) represent the cost per 
unit of effectiveness of switching to a more costly and more effective option. In report-
ing results for cost-effectiveness (CE) analyses, options that are strictly dominated are 
ruled out and no ICERs should be reported. Additionally, some options may be ruled 
out by extended dominance (i.e., there is a linear combination of two options that 
dominates an option not otherwise excluded by strict dominance). In order to plot 
the CE efﬁciency frontier both strictly and extendedly dominated options must be 
excluded. Calculating strict dominance (e.g., in Excel) is straightforward. However 
calculating extended dominance is more complex. METHODS: We present a method 
to exclude extendedly dominated options using an ICER matrix. To form an ICER 
matrix all options are rank ordered by cost. For a CE analysis with N options, the 
ICER matrix is an N x N-1 sized table, where the ﬁrst column represents the ICER 
from the least costly option to each more costly option, the second column represents 
the ICER from the second least costly option to each more costly option, etc.. Negative 
ICERs, representing strictly dominated options, are excluded from the table. Extended 
dominance is established by calculating whether the ICER for a non-strictly dominated 
option is greater than the ICER for at least one more costly option. If so, the option 
is rule out by extended dominance, otherwise not. We show how to perform the 
required calculations in Excel and how to graphically plot the CE efﬁciency frontier 
once all dominated and extendedly dominated options have been excluded. CONCLU-
SIONS: Strictly dominated and extendedly dominated options must be ruled out in 
order to plot the CE efﬁciency frontier. The ICER matrix is a systematic method to 
rule out strictly and extendedly dominated options.
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THE COST-EFFECTIVENESS SENSITIVITY CURVE: QUANTIFYING  
THE EFFECT OF INDIVIDUAL PARAMETER UNCERTAINTY IN A 
PROBABILISTIC MODEL
O’Day K, Meissner B, Bramley T
Xcenda, Palm Harbor, FL, USA
BACKGROUND: The cost-effectiveness acceptability curve (CEAC) graphically 
depicts the joint uncertainty in a probabilistic model by transforming the incremental 
cost-effectiveness ratio into a net-beneﬁt framework to represent the probability that 
a strategy is cost-effective over a range of willingness-to-pay (WTP) thresholds. By 
characterizing the joint distribution of costs and effects for all model parameters, the 
CEAC simpliﬁes the presentation of uncertainty compared to deterministic one-way 
and multi-way sensitivity analyses and allows decision makers to identify the preferred 
strategy based on their WTP threshold. However, in some instances presenting only 
the joint uncertainty may be a limitation of the CEAC. METHODS: We propose a 
method to graphically present the uncertainty contributed by a single parameter within 
a probabilistic model called the cost-effectiveness sensitivity curve (CESC). Like the 
CEAC, the y-axis of the CESC represents the probability that a strategy is cost-
effective. However, instead of WTP, the x-axis represents a speciﬁed range of values 
for a single model parameter. The CESC is generated by varying the chosen parameter 
over the speciﬁed range of values and calculating the net-beneﬁt at each value for each 
simulation based on the sampled values of the remaining model parameters without 
resampling (note: to effect the net-beneﬁt transformation the CESC is based on a single 
WTP threshold). Computationally, the CESC requires an additional series of calcula-
tions for each simulation corresponding to the desired number of points on the curve. 
The advantage of the CESC is that it probabilistically describes the effect of uncer-
tainty of a single model parameter on cost-effectiveness. This is particularly useful for 
ex-ante pricing decisions and for early phase go/no-go decisions based on an antici-
pated range of effectiveness. CONCLUSIONS: The CESC is a useful tool in speciﬁc 
decision making contexts for quantifying the contribution of a single model parameter 
to uncertainty within a probabilistic model.
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MEDICATION LABEL EVALUATION PROCESS MODEL: USING THE 
STRUCTURAL EQUATION MODELING APPROACH TO BETTER 
PREDICT PURCHASE INTENTION
Dwibedi N, Sansgiry S
University of Houston, Houston, TX, USA
OBJECTIVES: The objective of this study was to examine whether the Over-the-
Counter Medication Label Evaluation Process Model (OTC-LEPM) or its modiﬁed 
version explained consumer’s purchase intention better. METHODS: Data collected 
during an experimental ﬁeld study was reanalyzed using structural equation modeling 
(SEM). Purchase intention with regard to three OTC medications for pain was evalu-
ated using simulated product package labels for Acetaminophen, Ibuprofen and 
Aspirin. The experiment was conducted with consumers in the process of selecting an 
OTC product at local pharmacy stores. Endogenous variables were product knowl-
edge, product evaluation, attitude-toward-product label and purchase intention. An 
additional endogenous variable ease of use was used in the modiﬁed OTC-LEPM. 
Demographics collected were analyzed using descriptive analysis in SPSS. AMOS v17 
was used to conduct SEM and test whether OTC-LEPM or modiﬁed OTC-LEPM was 
the better model to explain the variables that predict purchase intention. RESULTS: 
A total of 336 consumers participated in the study. A chi-square value using the SEM 
approach for OTC-LEPM was 6262.390. The SEM for the modiﬁed OTC-LEPM 
indicated that iteration limit was reached (55000). Alternative model approach pro-
duced 3 models with slightly better chi-square value. A new model was built by 
combining alternative model approach and McFadden’s Choice Process. This model 
produced an improved ﬁt, producing a chi-square value of 4697 (df = 902, p < 0.0001). 
This model validated that knowledge signiﬁcantly causes attitude towards product 
label which directly and indirectly via product evaluation causes purchase intention 
and these causal links were statistically signiﬁcant. It indicated that only one exoge-
nous variable age was statistically signiﬁcant. CONCLUSIONS: The modiﬁed OTC-
LEPM may not be the best model to analyze consumer’s OTC medication purchase 
intention. Further research is needed to evaluate variables that can improve the under-
standing of consumer’s purchase intention.
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SYNCHRONIZATION OF RANDOM NUMBER STREAMS GREATLY 
ENHANCES EFFICIENCY OF PROBABILISTIC MODELS
Smolen LJ, Klein RW
Medical Decision Modeling Inc., Indianapolis, IN, USA
The inclusion of probabilistic components in health care models requires the imple-
mentation of random number sampling. Many microsimulation models use a single 
simple random number generator without concern for its properties. This limits the 
modeler’s ability to use the identical series of random numbers for alternative treat-
ment strategies or among comparators. Synchronization of model results between 
treatment arms within a model run is difﬁcult unless separate random streams are 
used for each source of variation. Synchronization of random number streams requires 
maintaining arrays of starting and current random number seeds. If each source of 
variation (e.g., times or probabilities of death and major events) has its own stream 
then the simulation of identical patients in all treatment arms is possible. By resetting 
the seed for each arm, the model results are impacted only by differences in model 
input point estimates (for ﬁrst-order analyses) or differences in the speciﬁed distribu-
tions of sampled model inputs (for second-order analyses). The impact of random 
number sampling is thus maximally correlated between treatments, and the differences 
in the occurrences of events common to both simulations, e.g., natural death, are not 
artiﬁcially inﬂated due to random sampling. Given a sufﬁcient number of replications, 
stochastic models usually produce stable results. This is because any further increase 
in the number of modeled replications will have minimal impact on the average-based 
model results. If the modeled result is the ratio of differences, such as an incremental 
cost effectiveness ratio (ICER), small differences in the denominator often drive the 
estimate, requiring a large number of replications. The allocation of common events, 
particularly natural death, to designated random streams minimizes the impact of 
random sampling on the model results. The number of model replications (and thus 
execution time) needed to produce stable ICERs may be reduced by as much as 90%.
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REVIEW OF COST EFFECTIVENESS STUDIES OF HIGH BUDGET 
IMPACT DRUGS
Aggarwal S1, White N2, Stevens CA3
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OBJECTIVES: The recently made coverage decisions by UK’s NICE, Scotland’s SMC 
and the allocation of $1.1Billion for comparative effectiveness research by the United 
States, are strong indicators of trends in pricing and reimbursement that are likely to 
be observed in the future. To gain an additional insight into these trends, we analyzed 
the cost effectiveness studies for the top ten highest selling drugs (∼$80–95B worldwide 
sales). METHODS: The Top 10 drugs were selected based on their worldwide sales. 
For this analysis, we segmented these drugs into categories as primary care, specialty, 
small molecules, biologics, therapy areas and availability of generic alternatives. We 
analyzed the cost effectiveness studies that were published in peer-reviewed journals. 
Search was conducted using generic names of the drugs and the phrase “cost effective-
ness” in abstract of the published study. RESULTS: During 2003–2008, the number 
of published studies on “cost effectiveness” have increased by more than 30%. Almost 
half of the published studies belong to—Remicade, Plavix and Enbrel. There is a large 
